 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXEPIN HCL increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDOXEPIN HCL[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDOXEPIN HCL[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"DOXEPIN HCL"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: DOXEPIN HCL: openfda: generic_name         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: substance_name         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: application_number         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behaviour [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of doxepin or any other antidepressant in a child, [0m
[31madolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults [0m
[31mbeyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are themselves associated with [0m
[31mincreases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual [0m
[31mchanges in behavior.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: boxed_warning: [0m[1;31m([0m[31mSee WARNINGS: CLINICAL WORSENING AND SUICIDE RISK, PRECAUTIONS: INFORMATION FOR PATIENTS, and PRECAUTIONS: PEDIATRIC USE[0m[1;31m)[0m[31m         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. Doxepin is not approved for use in pediatric [0m
[31mpatients.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: spl_product_data_elements: [0m[1;31m6[0m[31m PROPYLENE GLYCOL FERROSOFERRIC OXIDE TITANIUM DIOXIDE Ivory opaque ap;DXP25 white opaque         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: spl_product_data_elements: Doxepin HCL Doxepin HCL MAGNESIUM STEARATE SHELLAC DOXEPIN HYDROCHLORIDE DOXEPIN MICROCRYSTALLINE CELLULOSE GELATIN, UNSPECIFIED D&C YELLOW NO. [0m[1;31m10[0m[31m [0m
[31mSTARCH, CORN SODIUM LAURYL SULFATE POTASSIUM HYDROXIDE FD&C YELLOW NO.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: manufacturer_name         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Doxepin HCL is a medication with a boxed warning indicating that antidepressants like doxepin can increase the risk of suicidal thinking and behavior [0m[1;32m([0m[32msuicidality[0m[1;32m)[0m[32m in children, adolescents, [0m
[32mand young adults in short-term studies of major depressive disorder [0m[1;32m([0m[32mMDD[0m[1;32m)[0m[32m and other psychiatric disorders. The risk must be balanced with the clinical need for the medication. There is no increased [0m
[32mrisk of suicidality in adults over [0m[1;32m24[0m[32m and a reduced risk in adults aged [0m[1;32m65[0m[32m and older. It is not approved for use in pediatric patients, and families and caregivers should be advised to closely observe[0m
[32mand communicate with the prescriber. The medication contains ingredients such as propylene glycol, ferrosoferric oxide, titanium dioxide, magnesium stearate, shellac, microcrystalline cellulose, [0m
[32mgelatin, dyes, starch, sodium lauryl sulfate, and potassium hydroxide.[0m

[32mSOURCE: DOXEPIN HCL label[0m
[32mEXTRACT_START_END: DOXEPIN HCL: boxed_warning: Suicidality and[0m[32m...[0m[32mcommunication with the prescriber.[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Doxepin HCL is a medication with a boxed warning indicating that [0m
[34mantidepressants like doxepin can increase the risk of suicidal thinking and behavior [0m[1;34m([0m[34msuicidality[0m[1;34m)[0m[34m in children, adolescents, and young adults in short-term studies of major depressive disorder [0m[1;34m([0m[34mMDD[0m[1;34m)[0m[34m [0m
[34mand other psychiatric disorders. The risk must be balanced with the clinical need for the medication. There is no increased risk of suicidality in adults over [0m[1;34m24[0m[34m and a reduced risk in adults aged [0m[1;34m65[0m[34m [0m
[34mand older. It is not approved for use in pediatric patients, and families and caregivers should be advised to closely observe and communicate with the prescriber. The medication contains ingredients [0m
[34msuch as propylene glycol, ferrosoferric oxide, titanium dioxide, magnesium stearate, shellac, microcrystalline cellulose, gelatin, dyes, starch, sodium lauryl sulfate, and potassium hydroxide.[0m

[34mSOURCE: DOXEPIN HCL label[0m
[34mEXTRACT_START_END: DOXEPIN HCL: boxed_warning: Suicidality and[0m[34m...[0m[34mcommunication with the prescriber.[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes DOXEPIN HCL increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes DOXEPIN HCL increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"DOXEPIN HCL"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: DOXEPIN HCL: adverse_reactions: NOTE: Some of the adverse reactions noted below have not been specifically reported with doxepin use. However, due to the close pharmacological similarities [0m
[31mamong the tricyclics, the reactions should be considered when prescribing doxepin hydrochloride. Anticholinergic Effects: Dry mouth, blurred vision, constipation, and urinary retention have been [0m
[31mreported. If they do not subside with continued therapy, or become severe, it may be necessary to reduce the dosage. Central Nervous System Effects: Drowsiness is the most commonly noticed side [0m
[31meffect. This tends to disappear as therapy is continued. Other infrequently reported CNS side effects are confusion, disorientation, hallucinations, numbness, paresthesias, ataxia, extrapyramidal [0m
[31msymptoms, seizures, tardive dyskinesia, and tremor. Cardiovascular: Cardiovascular effects including hypotension, hypertension, and tachycardia have been reported occasionally. DOXEPIN HCL: [0m
[31madverse_reactions: Allergic: Skin rash, edema, photosensitization, and pruritus have occasionally occurred. Hematologic: Eosinophilia has been reported in a few patients. There have been occasional [0m
[31mreports of bone marrow depression manifesting as agranulocytosis, leukopenia, thrombocytopenia, and purpura. Gastrointestinal: Nausea, vomiting, indigestion, taste disturbances, diarrhea, anorexia, [0m
[31mand aphthous stomatitis have been reported. [0m[1;31m([0m[31mSee ANTICHOLINERGIC EFFECTS.[0m[1;31m)[0m[31m Endocrine: Raised or lowered libido, testicular swelling, gynecomastia in males, enlargement of breasts and galactorrhea in [0m
[31mthe female, raising or lowering of blood sugar levels, and syndrome of inappropriate antidiuretic hormone secretion have been reported with tricyclic administration. DOXEPIN HCL: adverse_reactions: [0m
[31mOther: Dizziness, tinnitus, weight gain, sweating, chills, fatigue, weakness, flushing, jaundice, alopecia, headache, exacerbation of asthma, angle closure glaucoma, mydriasis and hyperpyrexia [0m[1;31m([0m[31min [0m
[31massociation with chlorpromazine[0m[1;31m)[0m[31m have been occasionally observed as adverse effects. Withdrawal Symptoms: The possibility of development of withdrawal symptoms upon abrupt cessation of treatment after[0m
[31mprolonged doxepin administration should be borne in mind. These are not indicative of addiction and gradual withdrawal of medication should not cause these symptoms. To report SUSPECTED ADVERSE [0m
[31mREACTIONS, contact Ajanta Pharma USA Inc. at [0m[1;31m1[0m[31m-[0m[1;31m855[0m[31m-[0m[1;31m664[0m[31m-[0m[1;31m7744[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: precautions: Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular [0m
[31mimportance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite [0m[1;31m([0m[31mat least [0m[1;31m5[0m[31m weeks may[0m
[31mbe necessary[0m[1;31m)[0m[31m. Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or [0m
[31mthe other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels[0m
[31mwhenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6. DOXEPIN HCL: precautions: Doxepin is primarily metabolized by CYP2D6 [0m[1;31m([0m[31mwith CYP1A2 & CYP3A4 as [0m
[31mminor pathways[0m[1;31m)[0m[31m. Inhibitors or substrates of CYP2D6 [0m[1;31m([0m[31mi.e., quinidine, selective serotonin reuptake inhibitors [0m[1;31m[[0m[31mSSRIs[0m[1;31m][0m[1;31m)[0m[31m may increase the plasma concentration of doxepin when administered concomitantly.[0m
[31mThe extent of interaction depends on the variability of effect on CYP2D6. The clinical significance of this interaction with doxepin has not been systematically evaluated. MAO Inhibitors: Serious side[0m
[31meffects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious [0m
[31minitiation of therapy with doxepin. The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage [0m
[31minvolved. DOXEPIN HCL: precautions: Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants. [0m
[31mSerious anticholinergic symptoms [0m[1;31m([0m[31mi.e., severe dry mouth, urinary retention and blurred vision[0m[1;31m)[0m[31m have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine [0m
[31mtherapy is initiated. Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine. In patients who have been [0m
[31mreported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum [0m
[31mtricyclic antidepressant levels and compromise their therapeutic effects. Alcohol: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or [0m
[31munintentional doxepin overdosage. This is especially important in patients who may use alcohol excessively. DOXEPIN HCL: precautions: Tolazamide: A case of severe hypoglycemia has been reported in a [0m
[31mtype II diabetic patient maintained on tolazamide [0m[1;31m([0m[1;31m1[0m[31m gm/day[0m[1;31m)[0m[31m [0m[1;31m11[0m[31m days after the addition of doxepin [0m[1;31m([0m[1;31m75[0m[31m mg/day[0m[1;31m)[0m[31m. Drowsiness: Since drowsiness may occur with the use of this drug, patients should be [0m
[31mwarned of the possibility and cautioned against driving a car or operating dangerous machinery while taking the drug. Patients should also be cautioned that their response to alcohol may be [0m
[31mpotentiated. Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be started on low doses of doxepin and observed closely. [0m[1;31m([0m[31mSee PRECAUTIONSâˆ’GERIATRIC [0m
[31mUSE.[0m[1;31m)[0m[31m Suicide: Since suicide is an inherent risk in any depressed patient and may remain so until significant improvement has occurred, patients should be closely supervised during the early course of[0m
[31mtherapy. Prescriptions should be written for the smallest feasible amount. DOXEPIN HCL: precautions: Psychosis: Should increased symptoms of psychosis or shift to manic symptomatology occur, it may be[0m
[31mnecessary to reduce dosage or add a major tranquilizer to the dosage regimen. Pediatric Use-Safety and effectiveness in the pediatric population have not been established [0m[1;31m([0m[31msee BOX WARNING and [0m
[31mWARNINGSâ€”Clinical Worsening and Suicide Risk[0m[1;31m)[0m[31m. Anyone considering the use of doxepin in a child or adolescent must balance the potential risks with the clinical need. Geriatric Use: A determination [0m
[31mhas not been made whether controlled clinical studies of doxepin included sufficient numbers of subjects aged [0m[1;31m65[0m[31m and over to define a difference in response from younger subjects. Other reported [0m
[31mclinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the [0m
[31mlow end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. DOXEPIN HCL: precautions: The extent of[0m
[31mrenal excretion of doxepin has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections. Sedating drugs may cause [0m
[31mconfusion and oversedation in the elderly; elderly patients generally should be started on low doses of doxepin and observed closely. [0m[1;31m([0m[31mSee WARNINGS.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: boxed_warning: Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behaviour [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, [0m
[31madolescents, and young adults in short-term studies of major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. Anyone considering the use of doxepin or any other antidepressant in a child, [0m
[31madolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults [0m
[31mbeyond age [0m[1;31m24[0m[31m; there was a reduction in risk with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. Depression and certain other psychiatric disorders are themselves associated with [0m
[31mincreases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual [0m
[31mchanges in behavior. DOXEPIN HCL: boxed_warning: Families and caregivers should be advised of the need for close observation and communication with the prescriber. Doxepin is not approved for use in [0m
[31mpediatric patients. DOXEPIN HCL: boxed_warning: [0m[1;31m([0m[31mSee WARNINGS: CLINICAL WORSENING AND SUICIDE RISK, PRECAUTIONS: INFORMATION FOR PATIENTS, and PRECAUTIONS: PEDIATRIC USE[0m[1;31m)[0m[31m         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: warnings: Clinical Worsening and Suicide Risk Patients with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m, both adult and pediatric, may experience worsening of their depression and/or the [0m
[31memergence of suicidal ideation and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant [0m
[31mremission occurs. Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long-standing [0m
[31mconcern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of[0m
[31mshort-term placebo-controlled trials of antidepressant drugs [0m[1;31m([0m[31mSSRIs and others[0m[1;31m)[0m[31m showed that these drugs increase the risk of suicidal thinking and behavior [0m[1;31m([0m[31msuicidality[0m[1;31m)[0m[31m in children, adolescents, and [0m
[31myoung adults [0m[1;31m([0m[31mages [0m[1;31m18[0m[31m-[0m[1;31m24[0m[1;31m)[0m[31m with major depressive disorder [0m[1;31m([0m[31mMDD[0m[1;31m)[0m[31m and other psychiatric disorders. DOXEPIN HCL: warnings: Short-term studies did not show an increase in the risk of suicidality with [0m
[31mantidepressants compared to placebo in adults beyond age [0m[1;31m24[0m[31m; there was a reduction with antidepressants compared to placebo in adults aged [0m[1;31m65[0m[31m and older. The pooled analyses of placebo-controlled [0m
[31mtrials in children and adolescents with MDD, obsessive compulsive disorder [0m[1;31m([0m[31mOCD[0m[1;31m)[0m[31m, or other psychiatric disorders included a total of [0m[1;31m24[0m[31m short-term trials of [0m[1;31m9[0m[31m antidepressant drugs in over [0m[1;31m4400[0m[31m [0m
[31mpatients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of [0m[1;31m295[0m[31m short-term trials [0m[1;31m([0m[31mmedian duration of [0m[1;31m2[0m[31m months[0m[1;31m)[0m[31m of [0m[1;31m11[0m[31m [0m
[31mantidepressant drugs in over [0m[1;31m77[0m[31m,[0m[1;31m000[0m[31m patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs [0m
[31mstudied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. DOXEPIN HCL: warnings: The risk differences [0m[1;31m([0m[31mdrug vs placebo[0m[1;31m)[0m[31m, [0m
[31mhowever, were relatively stable within age strata and across indications. These risk differences [0m[1;31m([0m[31mdrug-placebo difference in the number of cases of suicidality per [0m[1;31m1000[0m[31m patients treated[0m[1;31m)[0m[31m are provided [0m
[31min Table [0m[1;31m1[0m[31m. Table [0m[1;31m1[0m[31m Age Range Drug-Placebo Difference in Number of Cases of Suicidality per [0m[1;31m1000[0m[31m Patients Treated Increases Compared to Placebo <[0m[1;31m18[0m[31m [0m[1;31m14[0m[31m additional cases [0m[1;31m18[0m[31m-[0m[1;31m24[0m[31m [0m[1;31m5[0m[31m additional cases [0m
[31mDecreases Compared to Placebo [0m[1;31m25[0m[31m-[0m[1;31m64[0m[31m [0m[1;31m1[0m[31m fewer case â‰¥[0m[1;31m65[0m[31m [0m[1;31m6[0m[31m fewer cases No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to [0m
[31mreach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. DOXEPIN HCL: warnings: However, there is [0m
[31msubstantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with [0m
[31mantidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months[0m
[31mof a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, [0m
[31mimpulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as [0m
[31mfor other indications, both psychiatric and nonpsychiatric. DOXEPIN HCL: warnings: Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the [0m
[31memergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic[0m
[31mregimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to [0m
[31mworsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. DOXEPIN HCL: warnings: Families and caregivers of [0m
[31mpatients being treated with antidepressants for major depressive disorder or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the [0m
[31memergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health [0m
[31mcare providers Such monitoring should include daily observation by families and caregivers. Prescriptions for doxepin should be written for the smallest quantity of tablets consistent with good [0m
[31mpatient management, in order to reduce the risk of overdose. Screening Patients for Bipolar Disorder: A major depressive episode may be the initial presentation of bipolar disorder. It is generally [0m
[31mbelieved [0m[1;31m([0m[31mthough not established in controlled trials[0m[1;31m)[0m[31m that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at [0m
[31mrisk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m


[31mCONTENT: DOXEPIN HCL: precautions: Information for Patients Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks [0m
[31massociated with treatment with doxepin and should counsel them in its appropriate use. A patient Medication Guide about â€œAntidepressant Medicines, Depression and other Serious Mental Illness, and [0m
[31mSuicidal Thoughts or Actionsâ€ is available for doxepin. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should [0m
[31massist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete [0m
[31mtext of the Medication Guide is reprinted at the end of this document. Patients should be advised of the following issues and asked to alert their prescriber if these occur while taking doxepin. [0m
[31mDOXEPIN HCL: precautions: Patients should be advised that taking doxepin hydrochloride capsules can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of [0m
[31mangle-closure glaucoma. Pre-existing glaucoma is almost always open-angle glaucoma because angle-closure glaucoma, when diagnosed, can be treated definitively with iridectomy. Open-angle glaucoma is [0m
[31mnot a risk factor for angle-closure glaucoma. Patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure [0m[1;31m([0m[31me.g., iridectomy[0m[1;31m)[0m[31m, if they[0m
[31mare susceptible. DOXEPIN HCL: precautions: Clinical Worsening and Suicide Risk: Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, [0m
[31mpanic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia [0m[1;31m([0m[31mpsychomotor restlessness[0m[1;31m)[0m[31m, hypomania, mania, other unusual changes in behavior, worsening of depression, and [0m
[31msuicidal ideation, especially early during antidepressant treatment and when the dose is adjusted up or down. Families and caregivers of patients should be advised to look for the emergence of such [0m
[31msymptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset, or [0m
[31mwere not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very close monitoring and[0m
[31mpossibly changes in the medication. DOXEPIN HCL: precautions: Drug Interactions: Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 [0m
[1;31m([0m[31mdebrisoquin hydroxylase[0m[1;31m)[0m[31m is reduced in a subset of the Caucasian population [0m[1;31m([0m[31mabout [0m[1;31m7[0m[31m%â€“[0m[1;31m10[0m[31m% of Caucasians are so-called â€œpoor metabolizersâ€[0m[1;31m)[0m[31m; reliable estimates of the prevalence of reduced P450 2D6 [0m
[31misozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants [0m[1;31m([0m[31mTCAs[0m[1;31m)[0m[31m when given [0m
[31musual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large [0m[1;31m([0m[1;31m8[0m[31m-fold increase in plasma AUC of the TCA[0m[1;31m)[0m[31m. In addition, [0m
[31mcertain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. DOXEPIN HCL: precautions: An individual who is stable on a given dose of TCA may become [0m
[31mabruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme [0m[1;31m([0m[31mquinidine; cimetidine[0m[1;31m)[0m[31m [0m
[31mand many that are substrates for P450 2D6 [0m[1;31m([0m[31mmany other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide[0m[1;31m)[0m[31m. While all the selective serotonin reuptake [0m
[31minhibitors [0m[1;31m([0m[31mSSRIs[0m[1;31m)[0m[31m, e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may [0m
[31mpose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.         [0m
[31mSOUR[0m[1;31mCE:D[0m[31mOXEPIN HCL label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information does not specifically mention an increase or decrease in the risk of angioedema associated with DOXEPIN HCL. However, allergic reactions such as skin rash, edema, and[0m
[32mpruritus have occasionally occurred, which could suggest a potential for allergic-type reactions including angioedema.[0m

[32mSOURCE: DOXEPIN HCL label[0m
[32mEXTRACT_START_END: DOXEPIN HCL: adverse_reactions: Allergic: Skin rash[0m[32m...[0m[32moccasionally occurred.[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information does not specifically mention an increase[0m
[34mor decrease in the risk of angioedema associated with DOXEPIN HCL. However, allergic reactions such as skin rash, edema, and pruritus have occasionally occurred, which could suggest a potential for [0m
[34mallergic-type reactions including angioedema.[0m

[34mSOURCE: DOXEPIN HCL label[0m
[34mEXTRACT_START_END: DOXEPIN HCL: adverse_reactions: Allergic: Skin rash[0m[34m...[0m[34moccasionally occurred.[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does DOXEPIN HCL increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler if DOXEPIN HCL increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the available information does not specifically mention an increase or decrease in the risk of angioedema associated with DOXEPIN HCL. However, allergic reactions such[0m
[32mas skin rash, edema, and pruritus have occasionally occurred, which could suggest a potential for allergic-type reactions including angioedema."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The FDA label for DOXEPIN HCL does not specifically mention an increase or decrease in the risk of angioedema. However, since allergic reactions like skin rash, edema, and pruritus have[0m
[32moccasionally occurred, there is a potential for allergic-type reactions that could include angioedema. The degree of risk for angioedema specifically is not detailed in the label, so it cannot be [0m
[32mstated with certainty whether DOXEPIN HCL increases or decreases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does DOXEPIN HCL increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler if DOXEPIN HCL increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the available information does not specifically mention an increase or decrease in the risk of angioedema associated with DOXEPIN HCL. However, allergic reactions such[0m
[34mas skin rash, edema, and pruritus have occasionally occurred, which could suggest a potential for allergic-type reactions including angioedema."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The FDA label for DOXEPIN HCL does not specifically mention an increase or decrease in the risk of angioedema. However, since allergic reactions like skin rash, edema, and pruritus have[0m
[34moccasionally occurred, there is a potential for allergic-type reactions that could include angioedema. The degree of risk for angioedema specifically is not detailed in the label, so it cannot be [0m
[34mstated with certainty whether DOXEPIN HCL increases or decreases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does DOXEPIN HCL increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler if DOXEPIN HCL increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the available information does not specifically mention an increase or decrease in the risk of angioedema associated with DOXEPIN HCL. However, allergic reactions such as [0m
[31mskin rash, edema, and pruritus have occasionally occurred, which could suggest a potential for allergic-type reactions including angioedema.[0m
[31m        -----[0m
[31m        Final answer: The FDA label for DOXEPIN HCL does not specifically mention an increase or decrease in the risk of angioedema. However, since allergic reactions like skin rash, edema, and [0m
[31mpruritus have occasionally occurred, there is a potential for allergic-type reactions that could include angioedema. The degree of risk for angioedema specifically is not detailed in the label, so it [0m
[31mcannot be stated with certainty whether DOXEPIN HCL increases or decreases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-DOXEPIN HCL[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe FDA label for DOXEPIN HCL does not specifically mention an increase or decrease in the risk of angioedema. However, since allergic reactions like skin rash, edema, and pruritus have occasionally [0m
[32moccurred, there is a potential for allergic-type reactions that could include angioedema. The degree of risk for angioedema specifically is not detailed in the label, so it cannot be stated with [0m
[32mcertainty whether DOXEPIN HCL increases or decreases the risk of angioedema.[0m
